The Factor VIII Bypassing Activity of Prothrombin Complex Concentrates: The Roles of Factor VIla and of Endothelial Cell Tissue Factor

Summary

An experimental model incorporating cultured endothelial cells (EC) was used to study the "factor VIII bypassing" activity of prothrombin complex concentrates (PCC), a property exploited in the treatment of hemophiliacs with alloantibodies to factor VIII. Two PCC preparations were ineffective as stimuli of tissue factor expression by EC. However, incubation with a combination of PCC plus endotoxin (lipopolysaccharide, LPS) or tumor necrosis factor (TNF) induced much greater tissue factor expression than was seen in response to either substance alone. PCC expressed an additional direct procoagulant activity at the EC surface, which could not be attributed to either thrombin or factor Xa, and which was diminished by an anti-tissue factor antibody. Therefore factor VIIa, which was detectable in both PCC preparations, likely provided this additional direct procoagulant activity at the EC surface. We also excluded the possibility that coagulation proteases contained in or generated in the presence of PCC are protected from inactivation by AT III. Therefore, PCC can indirectly bypass factor VIII by enhancing induced endothelial tissue factor expression, and also possess direct procoagulant activity, probably mediated by factor VIIa.

• References

• 1 Lusher JM, Shapiro SS, Palascak JE, Rao LVM, Levine PH, Blatt PM. and the Hemophilia Study Group. N Engl J Med 1980; 303: 421-5
• 2 Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier Al, Whitehurst DA. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8
• 3 Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-7
• 4 Walker FJ, Esmon CT. The effects of phospholipid and factor Va on the inhibition of factor Xa by antithrombin III. Biochem Biophys Res Commun 1979; 90: 641-7
• 5 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-91
• 6 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine and phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-7
• 7 Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-41
• 8 Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86: 1382-6
• 9 O'Brien DP, Giles AR, Tate KM, Vehar GA. Factor VIII bypassing activity of bovine tissue factor using the canine hemophilic model. J Clin Invest 1988; 82: 206-11
• 10 Chabbat J, Hampikian-Lenin S, Toully V, Gaillandre A, Pejaudier L, Steinbuch M. A human factor VIIa concentrate and its effects in the hemophilic A dog. Thromb Res 1989; 54: 603-12
• 11 Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-43
• 12 Teitel JM, Ni H-Y, Freedman JJ, Garvey MB. The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate. Thromb Haemostas 1988; 60: 226-9
• 13 Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood 1987; 70: 490-3
• 14 Teitel JM. Specific inhibition of endothelial cell proliferation by isolated endothelial plasma membranes. J Cell Physiol 1986; 128: 329-36
• 15 Gimbrone Jr MA. Culture of vascular endothelium. Prog Hemostas Thromb 1974; 8: 1-28
• 16 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-50
• 17 Zuckerman SH, Surprenant YM. Induction of endothelial cell/ macrophage procoagulant activity: synergistic stimulation by gamma interferon and granulocyte-macrophage colony stimulating factor. Thromb Haemostas 1989; 61: 178-82
• 18 Crossman DC, Carr DP, McVey JH, Pearson JD, Tuddenham EGD. Tissue factor: time course of production of mRNA and protein in human endothelium in response to lipopolysaccharide and phorbol ester. Circulation 1989; 80: 11-316 (Abstr)
• 19 Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986; 137: 1532-7
• 20 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-7
• 21 Johnsen ULH, Lyberg T, Galdal KS, Prydz H. Platelets stimulate thromboplastin synthesis in human endothelial cells. Thromb Haemostas 1983; 49: 69-72
• 22 Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor-VII: presence in factor IX concentrate and persistence in the circulation after infusion. Blood 1979; 53: 828-37
• 23 Mackie IJ, Seghatchian MJ. Analysis of the procoagulant activities of factor IX concentrates. Thromb Res 1982; 28: 499-507
• 24 White II GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-70
• 25 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30
• 26 Kettner C, Shaw E. The selective affinity labeling of factor Xa by peptides of arginine chloromethyl ketone. Thromb Res 1981; 22: 645-52
• 27 Seligsohn U, Osterud B, Rapaport SI. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-88
• 28 Barrowcliffe TW, Kemball-Cook G, Gray E. Factor VIII inhibitor bypassing activity: a suggested mechanism of action. Thromb Res 1981; 21: 181-6
• 29 Stern D, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 1985; 82: 2523-7
• 30 Rao LVM, Rapaport SI, Lorenzi M. Enhancement by umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 1988; 71: 791-6
• 31 Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1978; 53: 828-34
• 32 Jesty J. The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 1978; 185: 165-73
• 33 Kasper CK. Treatment of factor VIII inhibitors. In: Progress in Hemostasis and Thrombosis, Volume 9.. Coller BS. (ed) WB Saunders, Philadelphia,: 1989. pp 57-86
• 34 Schorer AE, Kaplan ME, Rao GHR, Moldow CF. Interleukin 1 stimulates endothelial cell tissue factor production and expression by a prostaglandin-independent mechanism. J Lab Clin Med 1986; 56: 256-9
• 35 Agrawal BL, Zelkowitz L, Hletko P. Acute myocardial infarction in a young hemophiliac patient during therapy with factor IX concentrate and epsilon aminocaproic acid. J Pediatr 1981; 98: 931-3
• 36 Schulman S, Johnsson H, Wiman B. Acute effects with reference to thrombogenicity and liver toxicity after injection of different coagulation factor concentrates. Haemostasis 1989; 19: 152-9